129 related articles for article (PubMed ID: 38663895)
1. Rapid onset pembrolizumab-induced inflammatory arthritis diagnosed using musculoskeletal ultrasound.
Harnden K; Di Matteo A; Howell K; Mankia K
BMJ Case Rep; 2024 Apr; 17(4):. PubMed ID: 38663895
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma.
Kobak S
Curr Drug Saf; 2019; 14(3):225-229. PubMed ID: 31132977
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab.
Zand Irani A; Almuwais A; Gibbons H
BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35039353
[TBL] [Abstract][Full Text] [Related]
4. IgA nephropathy after pembrolizumab therapy for mesothelioma.
Wang R; Das T; Takou A
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257374
[TBL] [Abstract][Full Text] [Related]
5. Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis.
Gómez-Puerta JA; Gente K; Katsumoto TR; Leipe J; Reid P; van Binsbergen WH; Suarez-Almazor ME
Rheum Dis Clin North Am; 2024 May; 50(2):161-179. PubMed ID: 38670719
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
Bas O; Ozbek A; Guven D; Aktepe O; Kılıc L; Kertmen N; Erman M
J Oncol Pharm Pract; 2020 Jul; 26(5):1230-1233. PubMed ID: 31735133
[TBL] [Abstract][Full Text] [Related]
7. Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer.
Melia A; Fockens E; Sfumato P; Zemmour C; Madroszyk A; Lafforgue P; Pham T
Joint Bone Spine; 2023 Jan; 90(1):105457. PubMed ID: 36116771
[TBL] [Abstract][Full Text] [Related]
8. A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapy.
Papaxoinis G; Anastasopoulou A; Laskari K; Diamantopoulos P; Benopoulou O; Gogas H
Medicine (Baltimore); 2020 Mar; 99(10):e19439. PubMed ID: 32150095
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report.
Abe K; Ishikawa Y; Fujiwara M; Yukawa H; Yanagihara T; Takei S; Arioka H; Kita Y
Medicine (Baltimore); 2022 Jan; 101(2):e28428. PubMed ID: 35029182
[TBL] [Abstract][Full Text] [Related]
10. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
Thomas S; Bae C; Joy-Ann T; Traverse W
J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
[TBL] [Abstract][Full Text] [Related]
12. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
[TBL] [Abstract][Full Text] [Related]
13. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
Yoshida S; Shiraishi K; Mito T; Sayama K
Clin Exp Dermatol; 2020 Oct; 45(7):908-911. PubMed ID: 32394515
[No Abstract] [Full Text] [Related]
14. Pembrolizumab in the Treatment of Breast Cancer.
Pivot X
N Engl J Med; 2022 Jul; 387(3):273-274. PubMed ID: 35857664
[No Abstract] [Full Text] [Related]
15. Rare, but Severe: Vasculitis and Checkpoint Inhibitors.
Lindner AK; Gruenbacher G; Schachtner G; Thurnher M; Pichler R
Eur Urol Focus; 2020 May; 6(3):609-612. PubMed ID: 31072806
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor-induced rheumatoid arthritis: insights into an increasingly common aetiology of polyarthritis.
Kwok TSH; Bell MJ
BMJ Case Rep; 2019 Feb; 12(2):. PubMed ID: 30819683
[TBL] [Abstract][Full Text] [Related]
17. Steroid-dependent polyarthritis induced by immune checkpoint inhibitor therapy successfully treated with bimekizumab.
Springer R; Lange K; Homey B; Meller S; Lindhof HH
Immunotherapy; 2024 Mar; 16(5):287-293. PubMed ID: 38264842
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
Jono M; Kinehara Y; Utsu Y; Tamura Y; Koseto M; Murakami T; Uota A; Ninomiya R; Komo S; Sumitani S; Sato B; Kasayama S; Tachibana I
Intern Med; 2020 Feb; 59(4):569-572. PubMed ID: 31666468
[TBL] [Abstract][Full Text] [Related]
19. A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
Tang Y; Zhao Z; Wang X; Zuo W; Zhang B; Yuan T; Fu Y
Immunotherapy; 2021 Apr; 13(6):483-489. PubMed ID: 33626915
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.
Simonsen AB; Kaae J; Ellebaek E; Svane IM; Zachariae C
J Am Acad Dermatol; 2020 Nov; 83(5):1415-1424. PubMed ID: 32320766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
